<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998554</url>
  </required_header>
  <id_info>
    <org_study_id>SHP640-302</org_study_id>
    <secondary_id>2016-002440-16</secondary_id>
    <nct_id>NCT02998554</nct_id>
  </id_info>
  <brief_title>Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo</brief_title>
  <official_title>A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational treatment is effective
      compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Resolution Status of SHP640 and Placebo as Measured by Bulbar Conjunctival Injection</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Bulbar conjunctival injection will be assessed based on a 0-4 scale which uses pictures from the validated bulbar redness (VBR) scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Resolution Status of SHP640 and Placebo as Measured by Watery Conjunctival Discharge</measure>
    <time_frame>Day 6</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of watery conjunctival discharge in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline. Watery conjunctival discharge will be assessed based on a 0-3 scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication Between SHP640 and Placebo as Measured by Negative Cell Culture-Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 6</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CC-IFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at base line as well as his/he r CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenovirus Viral Titer Assessed by Quantitative Polymerase Chain Reaction (qPCR)</measure>
    <time_frame>Day 6 and Day 8</time_frame>
    <description>qPCR test will be performed on all CC -IFA positive sample s at all visits to determine viral count in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoviral Eradication as Assessed by Cell Culture Immunofluorescence Assay (CC-IFA)</measure>
    <time_frame>Day 3, Day 8 and Day 12</time_frame>
    <description>Adenoviral eradication for the study eye is defined as negative CC-IFA in that eye. CC-IFA for each eye will be conducted using conjunctival swab samples collected at each visit to determine the presence of adenovirus. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution of Adenoviral Conjunctivitis</measure>
    <time_frame>Day 3, Day 8 and Day 12</time_frame>
    <description>Clinical resolution of adenoviral conjunctivitis is defined as the absence (score=0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Clinical Signs</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Individual Clinical Signs for bulbar conjunctival injection and watery conjunctival discharge will be assessed in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Clinical Score</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Global clinical score is the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Global Clinical Score</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Global clinical score is the sum of bulbar conjunctival injection and watery conjunctival discharge. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Modified clinical resolution is defined as a global clinical score of 0 or 1 in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Expanded clinical resolution is defined as a global clinical score of 0, 1, or 2 with neither injection nor discharge having a score of 2 in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Resolution</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>Time to clinical resolution based upon assessments will be analysed in the study eye. The study eye is defined based on subject's bulbar conjunctival redness and watery conjunctival discharge scores at baseline as well as his/her CC-IFA results at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of Cross-over Infection</measure>
    <time_frame>Day 3, Day 6, Day 8 and Day 12</time_frame>
    <description>The status of cross-over infection which is assessed by CC-IFA to a subject's fellow eye will be for subjects with only 1 infected eye at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of SHP640 as measured by adverse events (AEs)</measure>
    <time_frame>Day 1 up to Day 13</time_frame>
    <description>Safety and tolerability of SHP640, compared to placebo will be evaluated in the treatment of subjects with adenoviral conjunctivitis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Adenoviral Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>SHP640</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants instructed to instill 1 drop of SHP640 (0.1 percent [%] Dexamethasone and 0.6% povidone-iodine [PVP-I]) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP640</intervention_name>
    <description>Instill 1 drop of SHP640 (0.1 percentage Dexamethasone and 0.6% povidone-iodine [PVP-I]) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.</description>
    <arm_group_label>SHP640</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of any age at Visit 1.

          2. Have a positive AdenoPlus® test at Visit 1 in at least 1 eye.

          3. Have a clinical diagnosis of suspected adenoviral conjunctivitis in at least 1 eye
             (the same eye as the AdenoPlus positive eye) confirmed by the presence of the
             following minimal clinical signs and symptoms in that same eye.

          4. Be willing to discontinue contact lens wear for the duration of the study.

          5. Have a Best Corrected Visual Acuity (BCVA) of 0.60 logarithm of the Minimum Angle of
             Resolution (logMAR) or better in each eye as measured using an Early Treatment
             Diabetic Retinopathy Study (ETDRS) chart.

          6. Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          1. Have known or suspected intolerance or hypersensitivity to the investigational
             product, closely related compounds, or any of the stated ingredients.

          2. Prior enrollment in a FST100 or SHP640 clinical study.

          3. Subjects who are employees, or immediate family members of employees (who are directly
             related to study conduct), at the investigational site.

          4. Have a history of ocular surgical intervention within ≤ 6 months prior to Visit 1 or
             planned for the period of the study.

          5. Have a preplanned overnight hospitalization during the period of the study.

          6. Have active or history of ocular herpes.

          7. Have at enrollment or within ≤30 days of Visit 1, a clinical presentation more
             consistent with the diagnosis of ocular allergy, toxic conjunctivitis, or
             non-adenoviral ocular infection (eg, bacterial, fungal, acanthamoebal, other or
             parasitic).

          8. Other protocol defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@Shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye Care Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanuan Wang</last_name>
      <phone>925-686-2020</phone>
      <email>Yyw0219@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Clark Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull Eye Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaci Taylor</last_name>
      <phone>661-945-4502</phone>
      <phone_ext>237</phone_ext>
      <email>ktaylor@hecresearch.com</email>
    </contact>
    <investigator>
      <last_name>Janet Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Rodriguez</last_name>
      <phone>310-602-5640</phone>
      <email>tstudy1@wgeye.com</email>
    </contact>
    <investigator>
      <last_name>Brittney Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bowden Eye &amp; Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Montgomery</last_name>
      <phone>904-296-0098</phone>
      <email>jmontgomery@bowdeneye.com</email>
    </contact>
    <investigator>
      <last_name>Frank Bowden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medsol Clinical Research Center</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33948</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vasconcelos</last_name>
      <phone>941-623-9744</phone>
      <email>mvasconcelos@medsolcrc.com</email>
    </contact>
    <investigator>
      <last_name>David Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>International Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Perez</last_name>
      <phone>813-875-6588</phone>
      <email>michellew@irctampa.com</email>
    </contact>
    <investigator>
      <last_name>Bernard Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saltzer Medical Group</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Davis</last_name>
      <phone>208-463-3128</phone>
      <email>SSDavis@saltzermed.com</email>
    </contact>
    <investigator>
      <last_name>Ryan McKinnon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wohl Eye Center</name>
      <address>
        <city>Bloomingdale</city>
        <state>Illinois</state>
        <zip>60108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Steger</last_name>
      <phone>630-351-2030</phone>
      <email>michelle@wohleyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Lisa Wohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shire Call Center</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shire Call Center</last_name>
      <phone>866-842-5335</phone>
      <email>clinicaltransparency@shire.com</email>
    </contact>
    <investigator>
      <last_name>Shire physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fichte, Endl&amp; Elmer Eyecare</name>
      <address>
        <city>Niagara Falls</city>
        <state>New York</state>
        <zip>14304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Goodnick</last_name>
      <phone>716-828-8970</phone>
      <email>Kathy.goodnick@fichte.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Elmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Gonzales</last_name>
      <phone>832-280-3642</phone>
    </contact>
    <investigator>
      <last_name>Carlos Gonzales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chrysalis Clinical Research</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rian Farr</last_name>
      <phone>435-656-1704</phone>
      <email>RFarr@sgccr.com</email>
    </contact>
    <investigator>
      <last_name>Jason Hendrix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emanuelli Research &amp; Development Center, LLC</name>
      <address>
        <city>Arecibo</city>
        <zip>00613</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Perez</last_name>
      <phone>(787) 879-7722</phone>
      <email>dperez.erd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andres Emmanueli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Dotal de Investigaciones de Servicios de Salud</name>
      <address>
        <city>Carolina</city>
        <zip>00984</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy Ortiz-Ortiz</last_name>
      <phone>(787) 701-1121</phone>
    </contact>
    <investigator>
      <last_name>Enid Garcia-Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berrocal and Associates</name>
      <address>
        <city>San Juan</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Berrocal</last_name>
      <phone>787-725-9315</phone>
      <email>mariahberrocal@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Berrocal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Inclusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

